Document is current
Any future updates will be listed below
-
Authors
Syversen, Silje W https://orcid.org/0000-0003-2159-3696
Goll, Guro L
Jørgensen, Kristin K
Olsen, Inge C
Sandanger, Øystein
Gehin, Johanna E
Warren, David J
Sexton, Joseph
Mørk, Cato
Jahnsen, Jørgen
Kvien, Tore K
Bolstad, Nils
Haavardsholm, Espen A
-
Funding
Funding for this research was provided by:
Helse Sør-Øst RHF (1)
Helse Nord RHF (4)
Helse Vest Regionalt Helseføretak (2)
Helse Midt-Norge (3)
Diakonhjemmet (5)
- License Information
-
More Information
Article History
Received: 30 May 2019
Accepted: 17 September 2019
First Online: 6 January 2020
Ethics approval and consent to participate
: The NOR-DRUM study will be carried out in accordance with the declaration of Helsinki and the protocol has been approved by the Norwegian Regional Committees for Medical and Health Research Ethics ID 2016/1231. All patients will receive oral and written information and give their written informed consent before screening. Patients can withdraw their consent at any time. The study protocol, including the patient information and informed consent form to be used, has been approved by the regional ethics committee before enrolment of any patients into the study.
: Not applicable.
: SWS reports personal fees for speaking from Roche.GLG reports personal fees from AbbVie, Eli Lilly, Novartis, Pfizer, Roche, Sandoz, Orion Pharma, Celltrion and Boehringer Ingelheim.KKJ reports personal fees from Intercept, Norgine and Celltrion.ICJ reports personal fees from Pfizer.ØS declares that he has no competing interests.JG reports personal fees for speaking from Roche.DJW declares that he has no competing interests.JS declares that he has no competing interests.CM reports fees for speaking and/or consulting from Novartis, LEO Pharma, ACO, Petrified Nordic, Abbvie, Galderma Nordic, Celgene.TKK reports fees for speaking and/or consulting from AbbVie, Biogen, Celltrion, Egis, Eli Lilly, Hikma, MSD, Mylan, Novartis, Oktal, Orion Pharma, Hospira/Pfizer, Roche, Sandoz, Sanofi and UCB and has received research funding to Diakonhjemmet Hospital from AbbVie, BMS, MSD, Pfizer, Roche and UCB.JJ has served as a speaker, consultant or advisory board member for AbbVie, Astro Pharma, Boerhinger Ingelheim, BMS, Celltrion, Ferring, Hikma, Janssen, Meda, MSD, Napp Pharma, Norgine, Novartis, Orion Pharma, Pfizer, Pharmacosmos, Roche, Takeda, Tillotts and Sandoz.NB reports personal fees from Orion Pharma, Roche, Napp Pharmaceuticals, Pfizer and Takeda.EAH reports fees for speaking and/or consulting from AbbVie, Eli Lilly, Pfizer, Roche, Celgene, Janssen and UCB and has received research funding to Diakonhjemmet Hospital from AbbVie, MSD, Pfizer, Roche and UCB.
